🇺🇸 FDA
Pipeline program

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

R20423-HV-2555

Phase 1 other active

Quick answer

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis for Atopic Dermatits is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Atopic Dermatits
Phase
Phase 1
Modality
other
Status
active

Clinical trials